期刊文献+

PARP-1和caspase-3在结直肠肿瘤中的表达和意义 被引量:2

Expressions and Significance of PARP-1 and Caspase-3 in Colorectal Neoplasms
下载PDF
导出
摘要 背景:聚腺苷二磷酸核糖聚合酶-1(PARP-1)主要参与对DNA损伤的反应,caspase-3主要参与细胞凋亡的调控,两者与结直肠癌发生的关系尚不十分清楚。目的:探讨PARP-1和caspase-3在结直肠腺瘤和腺癌中的表达及其与肿瘤临床病理特征的关系。方法:以免疫组化方法检测59例结直肠腺瘤、70例结直肠腺癌和10例癌旁黏膜石蜡包埋标本中PARP-1和caspase-3的表达,分析腺瘤和腺癌组织中两者表达与肿瘤临床病理参数的相关性,以及两者间的相关性。结果:结直肠腺瘤和腺癌组织中,PARP-1的阳性表达率显著高于癌旁结直肠黏膜(55.9%和82.9%对20.0%,P〈0.05),caspase-3的阳性表达率显著低于癌旁结直肠黏膜(33.9%和28.6%对100.0%,P〈0.05)。结直肠腺瘤中,PARP-1的表达与腺瘤数目相关,caspase-3的表达与上皮内瘤变程度相关;结直肠腺癌中,PARP-1的表达与癌组织分化程度相关。PARP-1与caspase-3在结直肠腺瘤和腺癌组织中的表达无相关性。结论:PARP-1和caspase-3在结直肠腺癌的发生、发展过程中起有重要作用,两者联合检测对结直肠腺癌的早期诊断具有一定价值。 Background: Poly(ADP-ribose) polymerase-1 (PARP-1) is involved in cellular responses to DNA damage, while caspase-3 mainly regulates cell apoptosis. The relevance of PARP-1, caspase-3 and colorectal cancer is still uncertain. Aims: To investigate the expressions of PARP-1 and caspase-3 in colorectal adenoma and adenocarcinoma, and their relationships with the clinicopathologic characteristics of colorectal neoplasms. Methods: PARP-1 and caspase-3 expressions were determined immunohistochemically on paraffin-embedded specimens of 59 colorectal adenoma, 70 colorectal adenocarcinoma and 10 paracancerous tissues. Relationships between expressions of PARP-1 and caspase-3 and the clinicopathologic features of colorectal adenoma and adenocarcinoma, as well as the relevance of PARP-1 and caspase-3 in colorectal adenoma and adenocarcinoma were analyzed. Results: PARP-1 immunoreactivity was significantly higher in colorectal adenoma and adenocarcinoma than in paracancerous mucosa (55.9% and 82.9% vs. 20.0%, P〈0.05). In contrast, caspase-3 expression was significantly lower in colorectal adenoma and adenocarcinoma than in paracancerous mucosa (33.9% and 28.6% vs. 100.0%, P〈0.05). PARP-1 expression was significantly correlated with the number of adenoma and the differentiation of adenocarcinoma, while caspase-3 expression was significantly correlated with the degree of intraepithelial neoplasia of adenoma. PARP-1 expression was not correlated with caspase-3 expression in colorectal adenoma and adenocarcinoma. Conclusions: Both PARP-1 and caspase-3 may be involved in the pathogenesis and development of colorectal adenocarcinoma. Combined detection of these two markers may be valuable for the early diagnosis of colorectal adenocarcinoma.
出处 《胃肠病学》 2009年第2期83-87,共5页 Chinese Journal of Gastroenterology
基金 本课题由南京市社会发展科技计划项目资助(No.200701111)
关键词 聚腺苷二磷酸核糖聚合酶-1 半胱氨酸天冬氨酸蛋白酶 结直肠肿瘤 腺瘤 腺癌 Poly(ADP-Ribose) Polymerase-1 Caspases Colorectal Neoplasms Adenoma Adenocarcinoma
  • 相关文献

参考文献17

  • 1Virag L, Szabo C. The therapeutic potential of poly(ADP- ribose) polymerase inhibitors. Pharmacol Rev, 2002, 54 (3): 375-429.
  • 2吴运生,程清洲.大肠癌及腺瘤中caspase-3和bcl-2的表达及临床意义[J].数理医药学杂志,2003,16(4):300-302. 被引量:8
  • 3Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer, 1993, 72 (10): 2979-2985.
  • 4Nozaki T, Fujihara H, Watanabe M, et al. Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane. Cancer Sci, 2003, 94 (6): 497-500.
  • 5Conde C, Mark M, Oliver FJ, et al. Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. EMBO J, 2001, 20 (13): 3535-3543.
  • 6Hirai K, Ueda K, Hayaishi O. Aberration of poly (adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res,1983, 43 (7): 3441-3446.
  • 7Idogawa M, Yamada T, Honda K, et al. Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4foeta-catenin complex. Gastroenterology, 2005, 128 (7): 1919-1936.
  • 8Nosho K, Yamamoto H, Mikami M, et al. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer, 2006, 42 (14): 2374-2381.
  • 9Tomoda T, Kurashige T, Moriki T, et al. Enhanced expression of poly (ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol, 1991, 37 (4): 223- 227.
  • 10Shimizu S, Nomura F, Tomonaga T, et al. Expression of poly (ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance. Oncol Rep, 2004, 12 (4): 821-825.

二级参考文献34

  • 1张保华,王泽华,卢实.宫颈癌组织中caspase-3与nm23-H_1基因的表达及其意义[J].医药论坛杂志,2004,25(11):41-43. 被引量:4
  • 2贾晓青,钟宁,王菁华,张尚忠.NS-398降低结肠癌细胞系HT-29体外侵袭力[J].基础医学与临床,2004,24(5):547-551. 被引量:5
  • 3Nicholson DW, Thomberry N A, et al. Identification and inhibition of the ICG/CED3 protease necessary for mammalian apoptosis.Nature, 1995,376:37~43.
  • 4Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.Nature, 1990,384:334.
  • 5Colombel M, Symmans F, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol, 1993,143~390.
  • 6Iseki K, Tatsuata M, Uehara H, et al. Inhibition of angiogenesis as a mechanism for inhibition by 1 α-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rat. Int J Cancer, 1999,81(5): 730~733.
  • 7Brenner C, Kroemer G. The mitochondrion: decisive for cell death control? Signaling pathway in apoptosis. Hawood academic publishers, 1999,207~ 216.
  • 8Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science, 1998,281(5381):1305~1308.
  • 9Depraetere V, Golstein P. Dismantling in cell death: molecular mechanisms and relationship to caspase activation. Scand J Immunol, 1998,47(6) :523~531.
  • 10Krajewska M, Wang HG, Kraiewski S, et al. Immunohistochemical analysis of in vivo pattens of expression of CPP32(Cas-pase-3),a cell death protease. Cancer Res, 1997,57 (8) : 1605-1613.

共引文献55

同被引文献27

  • 1谢庆祥,林吓聪,韩聪祥,赵力.Caspase-3在肾细胞癌中表达及其意义[J].中国医学工程,2005,13(5):486-488. 被引量:4
  • 2高俊,陈洪雷.caspase-3、PARP蛋白在肺癌组织中的表达及临床意义[J].数理医药学杂志,2006,19(1):34-36. 被引量:4
  • 3王志强,黄志勇,陈孝平,张志发.人肝癌组织中PARP-1的表达与生物学特征的关系[J].世界华人消化杂志,2006,14(20):1995-1998. 被引量:6
  • 4Wallker R. The pathology of "precancerous" breast disease [J]. Pathol Ann u, 1995,29(7 ) :75-97.
  • 5Helleday T,Petermann E,Lundin C,et al. DNA repair pathways as targets for cancer therapy [ J 1. Nat Rev Cancer, 2008,8 ( 3 ) : 193-204.
  • 6Nguewa PA,Fuertes MA,Valladares B,et al. Poly (ADP-ribose) polymerases:homology, structural domains and functions. Novel therapeutical applications [ J]. Prog Biophys Mol Biol, 2005,88 (3) : 143-172.
  • 7Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers[J ]. N Engl J Med, 2009,361(2) : 123-134.
  • 8Dong F,Soubeyrand S,Hache RJ. Citivation of PARP-I in response to bleomycin depends on the Ku antigen and protein phosphatase 5 [ J ]. Oncogene, 2010,29 ( 14 ) : 2093-2103.
  • 9Donawho CK,Luo Y,Luo Y,et al. ABT-888,an orally active poly (ADP-ribose)polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models[ J ]. Clin Cancer Res,2007,13(9) : 2728-2737.
  • 10谭健中国和全球最新肿瘤发病率和死亡率解析[R]中国肿瘤登记年报,2013.

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部